You are here: Industry Insights > Amarin

News List

MHRA authorises Amarin’s heart drug Vazkepa pharmatimes
April 23, 2021
Amarin’s Vazkepa has received authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) as a treatment to reduce the risk of cardiovascular (CV) events in high-risk patients.
When it comes to Vascepa expansion, 'we can do this on our own' fiercepharma
August 01, 2019
Amarin’s fish-oil derivative Vascepa has been on a tear lately with a landmark outcomes trial and a $400 million cash raise in its rearview mirror. But taking the drug across the blockbuster plateau could present a challenge for a drugmaker as small as Am
Another win for Vascepa: Pricing watchdog ICER calls Amarin's fish-oil pill cost-effective fiercepharma
July 28, 2019
Amarin is betting big on its fish-oil derivative Vascepa with a $400 million cash raise to boost its marketing ahead of an expected label expansion. A nod of approval from a U.S. cost watchdog could kick those hopes into overdrive.
Amarin plots salesforce hiring binge to prep for new Vascepa approval fiercepharma
July 04, 2019
Amarin has been teasing big plans for Vascepa marketing when—and if—the med wins a new cardiovascular prevention approval this fall. And now we know just how big those plans are.
Amarin defends Vascepa's CV-prevention data against supplement makers eager to cash in fiercepharma
May 09, 2019
Amarin spent years, millions of dollars and a lot of willpower proving its fish oil-based drug Vascepa really could cut the risk of heart attacks, strokes and other cardiovascular problems. To make that effort pay off, it needs to keep that proof to itsel
Amarin’s Vascepa nabs ADA backing to cut heart risks, even ahead of FDA review fiercepharma
April 02, 2019
The cardiovascular outcomes results Amarin rolled out for its fish oil-derived Vascepa may not have impressed all……
Amarin rolls out more Vascepa heart benefits data to back label expansion fiercepharma
March 19, 2019
Amarin has rolled out new Vascepa data that could change the way doctors prevent heart disease. Monday, the company trumpeted more data showing its fish oil-derived Vascepa could significantly cut heart risks, and the drugmaker plans to add the benefits t
Amarin’s Vascepa cuts heart risks in key trial, but placebo noise fuels controversy fiercepharma
November 15, 2018
Some expecting a home-run win from Amarin’s heart drug Vascepa in cardiovascular benefits might leave the American Heart Association annual meeting feeling less excited.
Amarin says detailed REDUCE-IT results bolster CV risk reduction claims for Vascepa, but some question whether placebo used may have exaggerated benefit pharmafile
November 12, 2018
Detailed data from the REDUCE-IT cardiovascular (CV) outcomes study of Amarin's Vascepa (icosapent ethyl) presented at the American Heart Association (AHA) meeting
Believe it: Just as Amarin promised, Vascepa delivers big win in heart-risk study fiercepharma
September 30, 2018
WIth standard statin therapy covered by cheap generics, newer branded drugs have looked to outcomes studies to show they can reduce heart risks.

Previous page 1 2 Next page